Sintilimab
Sintilimab
Sintilimab is a monoclonal antibody used in the treatment of various types of cancer. It is an immune checkpoint inhibitor that targets the programmed cell death protein 1 (PD-1) pathway, which is a mechanism that tumors use to evade the immune system. By blocking this pathway, sintilimab helps to restore the immune system's ability to recognize and destroy cancer cells.
Mechanism of Action[edit | edit source]
Sintilimab is a fully human IgG4 monoclonal antibody that binds to the PD-1 receptor on T cells. The PD-1 receptor is an immune checkpoint that, when engaged by its ligands PD-L1 or PD-L2, inhibits T cell activation and allows cancer cells to escape immune surveillance. By inhibiting the interaction between PD-1 and its ligands, sintilimab reactivates T cells, enabling them to attack and kill cancer cells.
Clinical Applications[edit | edit source]
Sintilimab has been approved for use in several types of cancer, including:
Clinical trials are ongoing to evaluate its efficacy in other malignancies, such as esophageal cancer and hepatocellular carcinoma.
Development and Approval[edit | edit source]
Sintilimab was developed by Innovent Biologics in collaboration with Eli Lilly and Company. It was first approved in China in 2018 for the treatment of relapsed or refractory classical Hodgkin's lymphoma. Since then, its indications have expanded, and it is being studied in combination with other therapies to enhance its effectiveness.
Side Effects[edit | edit source]
As with other immune checkpoint inhibitors, sintilimab can cause immune-related adverse events (irAEs) due to increased immune activity. Common side effects include:
- Fatigue
- Rash
- Diarrhea
- Hepatitis
- Pneumonitis
Severe irAEs may require treatment with corticosteroids or other immunosuppressive agents.
Research and Future Directions[edit | edit source]
Ongoing research is focused on identifying biomarkers that predict response to sintilimab, optimizing combination therapies, and expanding its use to additional cancer types. Studies are also exploring its role in the neoadjuvant and adjuvant settings.
Also see[edit | edit source]
- Immune checkpoint inhibitors
- Monoclonal antibodies
- Cancer immunotherapy
- Programmed cell death protein 1
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
